endquote
Conclusion:
The information
is now overwhelming that cancer immunotherapy with GcMAF is highly
effective with no adverse effects. The National Institute of Health
(NIH) has wasted billions on ineffective treatments in the "War Against
Cancer" started by Nixon in the 1970's. I propose allocating a billion
dollars of NIH funding for research on GcMAF immunotherapy.
Do you think this would win the war and give us a CURE FOR CANCER?
You Betcha.
You might also be interested in: The GcMAF Book by Tim Smith MD
Do you think this would win the war and give us a CURE FOR CANCER?
You Betcha.
You might also be interested in: The GcMAF Book by Tim Smith MD
Jeffrey Dach MD
Links and References
1) http://www.saisei-mirai.or.jp/
GcMAF (Gc Protein-derived Macrophage-Activating Factor) For the treatment for cancer, HIV, and immune-system diseases. Dr Toshio Inui, MD. Graduated from Kyoto Prefectural University of Medicine in 1978. In 2010 he established Saisei Mirai Clinic in Kobe.
pdf file:
2012 Nature
2) nGcMAF: our next generation immunotherapy in nature-outlook-saisei-mirai
by Uto, Yoshihiro, Hitoshi Hori, Kentaro Kubo, Masamitsu Ichihashi, Norihiro Sakamoto, Martin Mette, Toshio Inui, and Trade Center. Nature 485 (2012): S67-S70.
by Uto, Yoshihiro, Hitoshi Hori, Kentaro Kubo, Masamitsu Ichihashi, Norihiro Sakamoto, Martin Mette, Toshio Inui, and Trade Center. Nature 485 (2012): S67-S70.
2013 By March 2013, Saisei Mirai have treated over 345 patients with GcMAF
3) http://ar.iiarjournals.org/content/33/7/2917.long
http://www.ncbi.nlm.nih.gov/pubmed/23780980
Anticancer Res. 2013 Jul;33(7):2917-9.
Clinical Experience of Integrative Cancer Immunotherapy with GcMAF.
Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, Sakamoto N.
Division of Food and Drug Evaluation Science, Department of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017,
http://www.ncbi.nlm.nih.gov/
Anticancer Res. 2013 Jul;33(7):2917-9.
Clinical Experience of Integrative Cancer Immunotherapy with GcMAF.
Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, Sakamoto N.
Division of Food and Drug Evaluation Science, Department of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017,
Immunotherapy has become an attractive
new strategy in the treatment of cancer. The laboratory and clinical
study of cancer immunotherapy is rapidly advancing. However, in the
clinical setting, the results of cancer immunotherapy are mixed. We
therefore contend that cancer immunotherapy should be customized to each
patient individually based on their immune status and propose an
integrative immunotherapy approach with second-generation group-specific
component macrophage activating factor (GcMAF)-containing human serum.
PATIENTS AND METHODS:The standard protocol of our integrative cancer immunotherapy is as follows: i) 0.5 ml GcMAF-containing human serum is administered intramuscularly or subcutaneously once or twice per week for the duration of cancer therapy until all cancer cells are eradicated; ii) hyper T/natural killer (NK) cell therapy is given once per week for six weeks; iii) high-dose vitamin C is administered intravenously twice per week; iv) alpha lipoic acid (600 mg) is administered orally daily; v) vitamin D3 (5,000-10,000 IU) is administered orally daily.
PATIENTS AND METHODS:The standard protocol of our integrative cancer immunotherapy is as follows: i) 0.5 ml GcMAF-containing human serum is administered intramuscularly or subcutaneously once or twice per week for the duration of cancer therapy until all cancer cells are eradicated; ii) hyper T/natural killer (NK) cell therapy is given once per week for six weeks; iii) high-dose vitamin C is administered intravenously twice per week; iv) alpha lipoic acid (600 mg) is administered orally daily; v) vitamin D3 (5,000-10,000 IU) is administered orally daily.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
2
1
1
